EGFR and non-small cell lung carcinoma: EGFR is over-expressed in 50 to 90% of non-small cell lung cancers (NSCLC) and carries activating mutations in 10 to 60% of cases depending on population10–12; these activating mutations can be up to 30-fold more catalytically active than wild-type EGFR13 and transduce signal even in the absence of ligand14.